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Background. Sulfhydryl groups (SH) are considered a key factor in redox sensitive reaction of plasma, and their modification could
be considered an expression of abnormal generation of oxygen free radicals. Methods. Fifty consecutive patients with acute brain
stroke were enclosed in this study. The plasma concentrations of SH groups were correlated to cytokines (IL-1b, IL-6, IL-8, TNF-
𝛼), plasma chitotriosidase (Chit), metalloprotease (MMP2–9), intercellular adhesion molecule-1 (ICAM-1). Results. The results
demonstrated a significant reduction of SH groups within 24 hours from the onset of an acute ischemic stroke, a reduction of
plasma IL-1b, IL-6, and IL-8, and an increase of Chit and TNF-𝛼 in relation to the stroke severity. Conclusion. The observation
of an intense microenvironment activation that follows the stroke and the correlation between SH levels and markers of immune
response suggest that, especially in stroke, is necessary to maintain the redox function to prevent the brain damage. The reduced
SH levels represent an attempt to neutralize the abnormal generation of free radicals. Since the reperfusion of brain after ischemic
event represents a severe oxidative stress, which must be corrected by regeneration of redox sensitive function, pharmacological
intervention could be beneficial in this setting.
1. Introduction
Thiols contain functional SH groups within conserved cys-
teinyl residue, and thiol-containing proteins are now recog-
nised as key players in redox sensitive reactions of plasma [1].
Their redox sensing abilities are thought to occur by electron
flow through the sulfhydryl side chain. The majority of thiols
present in cellular proteins are within a highly reducing
environment and therefore protected, or buffered, against
oxidation [2, 3]. Only protein as albumin with accessible thiol
groups and high oxidation potentials are likely to be involved
in redox mechanisms [4].
Several evidences demonstrate that such thiol-containing
proteins are sensitive to thiol modification when exposed to
changes in redox state of different tissues [5].
Plasma is the principal source of reduced thiols: their con-
centration is about 500 umol/L, they have a high molecular
mass, and they are chiefly attributable to albumin [6]. In fact,
antioxidant functions of albumin are linked to its ability to
bind transition metal ions and bilirubin, and to the radical
scavenging properties of its thiol groups [7]. Albumin’s redox
active thiol groups are predominantly in the reduced state.
In fact, albumin thiol groups can play an important role
in extracellular redox balance and subsequent signalling
pathways [8]. In the brain, the redox reaction is maintained
by ascorbic acid, which is introduced by meals, and it is
maintained in the redox status inside the brain, where it
protects the cerebral structures from the oxidation [9].
Stroke is a frequent neurological accident in old age
and its prevalence in Western countries is high [10]. After
an acute brain event, the early glial and endothelial cells
are induced to produce transcription of tumour necrosis
factor (TNF-𝛼) and interleukin IL-6, which is followed by
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a cascade of modulator inflammatory pathways [11]. Local
endothelia is transformed into a prothrombotic state allowing
peripheral mono- and polymorphonuclear cytotoxic cells
to be chemoattracted into the lesion site [12, 13]. With a
few exceptions [14], a relationship between the extent of
the brain damage and the early increase of TNF-𝛼 and IL-
6 plasma levels has generally been reported in stroke [12–
14]. Though the topic remains controversial, this process
induces an abnormal generation of oxygen free radicals by
microenvironment cells. Moreover, infiltrated macrophages
contribute further to brain damage through the synthesis
of pro- and anti-inflammatory cytokines, including TNF-
𝛼 and IL-10 [15]. Relationships between the extent of brain
damage and the plasma level of TNF-𝛼, IL-6, and, recently,
chitotriosidase (Chit), a marker of macrophage activation,
are reported, though usually in strict relation to pre-existing
and concomitant infectious inflammatory diseases [16]. Our
group demonstrated that this response is generated also in
absence of infection or other mechanism of macrophage
activation [17], limiting this phenomenon to the ischemic
event. In these studies, plasma chitotriosidase and TNF-𝛼
correlated to the extent of stroke severity and to CT lesion
volume, and the levels of these two markers to date could be
considered the more sensible parameters to follow the stroke
event.
The aim of this study is to evaluate and try to correlate
the plasma concentrations of SH groups to brain damage
volume, to serum cytokines (IL-1b, IL-6, IL-8, TNF-𝛼),
plasma chitotriosidase (Chit), metalloprotease (MMP2–9),
intercellular adhesion molecule-1 (ICAM-1), and to thioles
(cysteine, cysteinylglycine, homocysteine, and glutathione),
in 50 consecutive patients with acute brain ischemia without
concomitant symptoms or signs of inflammatory infectious
diseases. The evaluation of these possible mediators of stroke
could permit to better characterize the redox reaction in the
pathogenesis of stroke damage.
2. Material and Methods
2.1. Patients. Fifty consecutive Caucasian patients with an
acute ischemic stroke, 30 males and 20 females, mean age
64 (range 40–82), were enrolled for this study at Institute of
Neurology, University of Sassari, Italy. Blood samples were
drawn within 24 hours after stroke onset and before pharma-
cologic intervention. Samples were centrifuged and stored at
−80∘C until assayed. Exclusion criteria were the clinical evi-
dence of infectious, inflammatory, and autoimmune diseases,
malignancy, severe cardiac or renal or hepatic diseases, recent
transient ischemic attack or previous ischemic-hemorrhagic
strokes, atheromatous diseases, arteriosclerotic heart disease,
hypertension, and pulmonary diseases, anticoagulant or
acetylsalicylic acid therapies. An informed consent to the
study was obtained from all patients or their relatives, and
the protocol of study was approved by Ethical Committee of
Sassari University.
All patients underwent repeated neurological examina-
tions, electrocardiography and ultrasound tomography of
carotid and vertebral arteries. Stroke severity was evaluated
Table 1: National institutes of health stroke scale.
Score Stroke severity
0 No stroke symptoms
1–4 Minor stroke
5–15 Moderate stroke
16–20 Moderate to severe stroke
21–42 Severe stroke
and scored by administering the National Institutes of Health
Stroke Scale (NIHSS) on admission (0–42). NIHSS provides
optimal discrimination of 30-day mortality risk, more than
75% for patients with a score of at least 40. The NIHSS is a
tool used by healthcare providers to objectively quantify the
impairment caused by a stroke.The NIHSS is composed of 11
items, each of which scores a specific ability between 0 and 4.
For each item, a score of 0 typically indicates normal function
in that specific ability, while a higher score is indicative of
some level of impairment. The individual scores from each
item are summed in order to calculate a patient’s total NIHSS
score. The maximum possible score is 42, with the minimum
score being a 0 (Table 1).
Brain CT was routinely performed on patient admission
and at 7 days by means of a spiral-CT HISPEED/LX/I (Gen-
eral Electric, USA). Each scan was 120KV, 160mA, 5mm
thickness, and 2 sec acquisition time. To avoid imprecise
estimations of the lesion volume, due to the different three-
dimensional conformation of the lesion, we used an accurate
technique for calculating the volume of ischemic brain lesion
according with the Cavalieri’s principle, as described [14].
A control group represented by 20 healthy subjects, mean
age 55 (range 35–70), not suffering of cardiovascular disease,
atheromatous diseases, arteriosclerotic heart disease, hyper-
tension, pulmonary diseases, and carotid atherosclerosis, was
included in this study.
2.2. Cytokines. Enzyme-linked immunosorbent assay
(ELISA) tests for human IL-1b, IL-6, and IL-8 and human
TNF-𝛼 (Euroclone, Switzerland) were performed at the
Institute of Neurology, University of Sassari, Italy, according
to indications and suggestions of the manufacturer.
VCAM-1 (vascular cell adhesion molecule), ICAM-1
(intercellular adhesion molecule 1), and BDNF (brain-
derived neurotrophic factor) were measured by enzyme-
linked immunosorbent assay (ELISA). Values were expressed
as pg/mL while VCAM-1 was expressed as ng/mL. The
intra-assay imprecision was <5%, whereas the interassay
imprecision was <8%. MMP2–9 was measured by the
zymogram method. The gelatinolytic activity is given in
arbitrary units (units/ug protein).
2.3. Thioles. Plasma thioles (cysteine, cysteinylglycine,
homocysteine, glutathione) were measured in HPLC and
expressed in 𝜇mol/L at the Clinical Biochemistry Laboratory
of Catholic University, Rome, Italy. Inter-assay coefficient
of variation was 3.6%, calculated by measuring 15 replicates
of a serum sample in the same day. Plasma homocysteine >
15 𝜇mol/L was considered elevated.
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Table 2: Clinical and laboratory parameters of 50 patients with brain stroke divided in function of NIHSS score ≤30 and >30.
Age (yrs) VCAM BDNF ICAM MMP2–9
(A) NIHSS ≤ 30
𝑛. 30
(M. 20, F. 10)
67.3 ± 13.0 519 ± 205 43.23 (13.94–337.4) 248.6 ± 86.6 124.2 ± 64.1
(B) NIHSS > 30
𝑛. 20
(M. 11, F. 9)
70.3 ± 7.98 683.2 ± 404.0 121.8 (20–1303.9) 360.35 ± 179.71 239.6 ± 152.5
A versus B 𝑃 = 0.36 𝑃 = 0.064 𝑃 = 0.0001 𝑃 = 0.005 𝑃 = 0.0006
Control groups 55 (35–70) 15.96 ± 4.024 14.24 ± 6.88 201.2 ± 55.0 —
VCAM: Cytokine-induced cell adhesion molecule (ng/mL); BDNF: Brain-derived neurotrophic factor (pg/mL); ICAM: intercellular adhesion molecules
(pg/mL); MMP2–9: matrix metalloprotease 2–9 (units/ug protein).
Table 3: Cytokines (pg/mL), TNF-𝛼, TC volume, Chit (nmol/mL/h) and SH groups (mmol/L) in 50 patients with brain stroke divided in
function of NIHSS score ≤30 and >30.
Parameters IL-1b IL-6 IL-8 TNF-𝛼 TC mm3 Chit SH groups
(A) NIHSS ≤ 30
𝑛. 30
(M. 20, F. 10)
212.42 (4.1–1096) 12.23 ± 4.53 74.64 ± 16.47 52.74 ± 26.86 617 (355–5998) 21.90 ± 15.62 121.94 ± 72.95
(B) NIHSS > 30
𝑛. 20
(M. 11, F. 9)
166.5 (0.2–975.08) 9.55 ± 5.71 60.32 ± 16.36 225.32 ± 163.60 6611 (185–20836) 50.35 ± 35.36 80.63 ± 47.88
A versus B 𝑃 = 0.99 𝑃 = 0.071 𝑃 = 0.004 𝑃 = 0.0001 𝑃 = 0.0001 𝑃 = 0.0003 𝑃 = 0.030
Control groups 0–2.4 0.0–5.6 1.9–17.4 0.0–13.3 — 0.0–25 578.6 ± 63.6
2.4. Chit Activity. Chit activity was measured in plasma
according to the method reported in Sotgiu et al. [17],
at Department of Pediatrics, University of Catania, Italy.
Chit activity was measured as nanomoles of substrate
(4-methylumbelliferyl-beta-D-N,N󸀠,N󸀠󸀠triacetylchitotriose,
Sigma Chemical Co., USA). Briefly, Chit activity was
measured incubating 5 𝜇L of undiluted plasma with 100𝜇L of
a solution containing 22mMol/L of the fluorogenic substrate
4-methylumbelliferyl-beta-D-N,N,N-triacetylchitotriose
(Sigma Chemical Co.) in 0.5M citrate phosphate buffer pH
5.2, for 15min at 37∘C. The reaction was stopped by using






buffer, pH 10.7. The
fluorescence of formed 4-methylumbelliferone was read
on a Hitachi 2500 fluorometer, at 365 nm excitation and
450 nm emission. Chit activity was expressed as nanomoles
of substrate hydrolyzed per milliliter per hour (nmol/mL per
h). Patients with plasma Chit activity below 2.5 nmol/mL per
h were considered as Chit deficient.
2.5. Dosage of SH. SH groups were evaluated according to
Ellman reaction [18] at the Clinical Biochemistry Laboratory
of Catholic University, Rome, Italy, performing the spec-
trophotometer measurements on an automated chemistry
analyser (OLYMPUS 400).The assay is based on the reaction
of the SH groups with 5,5󸀠-dithiobis-2-nitrobenzoic acid
(DTNB, 2.5mM) in Tris-HCl 0.25M and EDTA 20mM
(pH 8.2) that develops a yellow-coloured compound, which
absorbs at 405 nm. The calibration was obtained by using
GSH 1000 𝜇M solution as standard. Intra-assay imprecision
was <5%, calculated by measuring the same sample in ten
different days. The method is linear up to 10mM/L, and the
sensitivity is 10mM/L. A control group was selected among
healthy individuals who underwent for health balance and
resulted in good conditions at the clinical examination.
2.6. Statistical Analysis. Clinical data and inflammatory
biomarkers were expressed as median and range and/or
mean ± SD where possible. Differences between groups
were evaluated through the Mann-Whitney Rank Sum Test.
Correlations between inflammatory markers and clinical
variables were assessed by using the Spearman Rank Order
Correlation coefficient (𝑟), and the 𝑃 value was considered
significant when <0.05.
3. Results
3.1. Patients and Outcome. The median NIHSS score was
30 (range 0–42). The intrinsic property of the NIHSS scale
(Table 1) allowed us stratifying patients in two groups, with
better (NIHSS score ≤ 30; 30 patients) and worse outcome
(NIHSS score of at least >30; 20 patients). The clinical
parameters in the two groups are reported in Table 2. A
significant difference was found for VCAM and BDNF,
ICAM, and MMP2–9 between the two groups. The VCAM,
BDNF, and ICAMvalues were higher than in healthy controls
(Table 2).
3.2. Cytokines, Chitotriosidase, SH Groups, and Thioles.
The SH concentration was significantly lower (104.5 ±
67.6mmol/L) in stroke patients compared to healthy controls
(578.6± 63.6mmol/L) (𝑃 = 0.0001) and significantly lower in




















y = 0.1659x + 13.09
P < 0.05
r = 0.78
Figure 1: Correlation between TNF-𝛼 and chitotriosidase in 50



















y = 0.1605x + 0.2831
P < 0.0001
r = 0.57
Figure 2: Correlation between homocysteine and glutathione in 50
patients with brain stroke.
Cytokines as IL-6 and IL-8 were higher in patients with
NIHSS score <30 (𝑃 = 0.071 and 𝑃 = 0.004, resp.), but the
IL-1bwas not significantly higher in the same patients. TNF-𝛼
and chitotriosidase were higher in patients with NIHSS score
>30 (𝑃 = 0.0001 and 𝑃 = 0.0003 resp.) compared to that with
NIHSS score <30 (see Table 3). The median lesion volume
was 987mm3, significantly larger (𝑃 < 0.05) in patients
with worse outcome (median 6611mm3; range 185–20836) as
compared to those with better outcome (median 617, range
355–5998). A significant correlationwas found betweenTNF-
𝛼 and Chit (𝑃 < 0.05) (see Figure 1).
The thioles were all in the normal range for age, and the
slight differences between the two groups NIHSS ≤30 or >30
were not significant except glutathione that was lower in all
patients (see Table 4).The correlation between homocysteine
and SH was not significant (𝑃 = 0.84). A direct positive
correlation was found between lesion volume and NIHSS
score (𝑟 = 0.59, 𝑃 = 0.01) and negative with SH groups
(𝑟 = −0.60, 𝑃 = 0.0001). Significant correlation was found
between SH and all the other considered parameters with
exception of TNF-𝛼 and ICAM (see Table 5).
Significant correlations were found between homocys-
teine and glutathione (𝑃 < 0.0001) and between SH and
glutathione (𝑃 = 0.04) (see Figures 2 and 3).
4. Discussion
There is a strict relation among the extension of tissue
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y = 11.864x + 88.198
P = 0.04
r = 0.29
Figure 3: Correlation between SH and glutathione in 50 patients
with brain stroke.
radicals [19], alteration of vascular reactivity with migration
of peripheral leukocyte, and increase in cytokine release [12–
14, 20–22]. In our study, we found a significant reduction
of SH groups within 24 hours from the onset of an acute
ischemic stroke, an increase of plasma TNF-𝛼 and Chit,
and a reduction of IL-6 and IL-8 in relation to the stroke
severity. Moreover, IL-6 and IL-8 directly correlate with SH
groups consumption, while Chit and SH correlate negatively,
especially in patients with worse outcome (see Table 5).
Several studies have demonstrated that the level of IL-6
directly relates to both fever and severity of stroke [16–19, 23],
which in turn is directly related to the strength of the acute
phase. This demonstrates that the innate reaction of stroke
is probably due exclusively to the macrophage activation,
secondary to the ischemic event.
In this study, plasma Chit and TNF-𝛼 correlated to the
extent of the stroke severity, and CT lesion volume and the
level of these two marker to date could be considered the
more sensible parameters in the followup of the stroke event,
as well as IL-6 is considered a marker of the acute event [24].
There are several links between macrophage activation
and stroke and infiltrated macrophages, which may con-
tribute to brain damage through a group of potentially neuro-
toxic factors such as proinflammatory cytokines, free radicals,
glutamate, and metalloproteases [25]. The modification of
SH groups in the poststroke period may be considered the
consequence of free radical generation. The reduced SH
levels may represent a tentative to neutralize the abnormal
generation of free radicals.
However, on this topic many questions remain to be
answered. For example, why chemoattracted or perhaps
resident macrophages such as microglia do activate their
gene to produce Chit and other cytokines, showing a direct
influence on the tissue damage or they simply reflect an
epiphenomenon of a pre-existing situation?We cannot argue
for any such hypotheses yet. Our results indicate that
Chit activity possibly represents the hallmark of an innate
macrophage response, and this activation correlates with the
severity of stroke [17].This parameter could be a novelmarker
of stroke in addition with other cytokines (IL-6 and IL-
8) [14], even if the cytokine upregulation follows as a fall
mechanism not sufficiently regulated, which worse often the
clinical course of neurological event.
Disease Markers 145
Table 4: Thioles (𝜇mol/L) in 50 patients with brain stroke divided in function of NIHSS score ≤30 and >30.
Parameters Cysteine Cysteinylglycine Homocysteine Glutathione
(A) NIHSS ≤ 30
𝑛. 30
(M. 20, F. 10)
196.58 ± 97.65 28.16 ± 19.20 7.93 ± 3.84 1.81 ± 1.81
(B) NIHSS > 30
𝑛. 20
(M. 11, F. 9)
206.72 ± 104.7 26.30 ± 16.79 9.22 ± 7.86 1.35 ± 1.18
A versus B 𝑃 = 0.72 𝑃 = 0.72 𝑃 = 0.44 𝑃 = 0.32
Controls groups 193 ± 39.8 24.6 ± 6.2 9.3 ± 3.7 3.05 ± 2.0
Table 5: Spearman rank order correlation of 50 patients with brain stroke.
All patients Age mm3 NIHSS SH IL-1b IL-6 IL-8 TNF-𝛼 Chit MMP2–9 ICAM VCAM
Age
𝑟 0 no no 0.219 No No No No No No No No
𝑃 0.0125
mm3
𝑟 0 0.59 −0.60 No No No No No No No No
𝑃 0.01 0.0001
NIHSS
𝑟 0 No No −0.415 −0.351 0.816 0.435 0.488 0.497 0.363
𝑃 0.0029 0.0126 0.000 0.0017 0.000 0.000 0.0098
SH
𝑟 0 No 0.374 0.331 No −0.296 −0.469 No 0.002
𝑃 0.015 0.016 0.0371 0.002 0.52
IL-1b
𝑟 0 0.337 No No No No No No
𝑃 0.0171
IL-6
𝑟 0 No −0.296 −0333 −0.395 −0.507 No
𝑃 0.0371 0.0182 0.0047 0.000
IL-8
𝑟 0 −0.355 No −0.306 No No
𝑃 0.0117 0.0310
TNF-𝛼
𝑟 0 0.479 0.371 0.470 No
𝑃 0.000 0.0082 0.000
Chit
𝑟 0 No 0.535 No
𝑃 0.000
MMP2–9









Another point to consider should be the observation that
the patients with stroke could be smokers, alcohol users, or
affected by pathologies that reduce the redox status [26, 27]
and determine an increase of homocysteinemia. One of the
potential injurious effects of hyperhomocysteinemia in the
stroke is the free radical generation [28].
In our study, the homocysteine level was found normal,
thus indicating that the redox status precedent the acute
stroke [29] was normal. The observation of a microenviron-
ment activation, which follows the stroke and the correlation
between SH levels andmarkers of immune response confirms
other similar studies [20, 21], but suggests that in stroke is
necessary to maintain the redox function to prevent and in
particular to contain the brain damage determined by the
ischemic event.
Since oxidative stress plays an important role in acute
ischemic stroke pathogenesis, free radical formation, and
subsequent oxidative damage may be a determinant factor
in stroke severity. In fact serum levels of nitric oxide (NO),
malondialdehyde (MDA), and glutathione (GSH) were mea-
sured within the first 48 h of stroke [30] and correlated with
the clinical outcomes.These results suggest deleterious effects
of oxidative stress on clinical outcome in acute ischemic
stroke and the variation of GSH levels may be an adaptive
mechanism during this period.
Since the reperfusion of brain after ischemic event
represents a severe oxidative stress that must be corrected
by regeneration of redox function [31], a pharmacological
intervention could be beneficial in this setting.
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